We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Lonza Initiates Large Scale Production Capacity and Technology Platform for Antibody Drug Conjugates
News

Lonza Initiates Large Scale Production Capacity and Technology Platform for Antibody Drug Conjugates

Lonza Initiates Large Scale Production Capacity and Technology Platform for Antibody Drug Conjugates
News

Lonza Initiates Large Scale Production Capacity and Technology Platform for Antibody Drug Conjugates

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Lonza Initiates Large Scale Production Capacity and Technology Platform for Antibody Drug Conjugates"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Global life science company Lonza Group Ltd plans to start large scale production of Antibody Drug Conjugates. This emerging class of product is utilized primarily in the treatment of cancer.

In contrast to other therapies, this antibody treatment promises more accurately targeted application possibilities, and as a result, increased effectiveness. The manufacture of Antibody Drug Conjugates involves coupling of a highly active chemical substance with a biotechnologically manufactured antibody.

Lonza’s activities in this technology area include investment in a new production unit and in supporting development and analytical laboratories, all to be located in Visp, Switzerland.

Construction of the commercial scale plant in Visp began in the last quarter of 2006. Stage I is expected to be on line in 2008. The plant will initially be capable of producing over 100 kg of antibody drug conjugates per year and future expansion plans are built into the design. Currently Lonza is operating laboratory scale production and will bring small scale pilot facilities on stream in 2007.

Uwe Bohlke, Head of Exclusive Synthesis of Lonza, commented: “With the investment in this new technology, Lonza will enter an emerging, high-growth business segment, which promises significant opportunities and potential. It is a perfect match with Lonza’s capabilities and technologies in both chemical and mammalian anti-body manufacture. We are delighted to be able to collaborate with the leading companies in this market.”

Advertisement